ReviewBiomarker research2020
Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance.
Review in Biomarker research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic, diagnostic and clinicopathological roles of tsRNAs: a meta-analysis in breast cancer.European journal of medical research · 2024Pooled it
- Review
- Identification of plasma tRNA-derived small RNA i-tRF-15:31-Lys-CTT-1 as a biomarker for diagnosis and prognosis of pulmonary arterial hypertension.Non-coding RNA research · 2025Article
- Differential expression of tRNA-derived small RNAs in Juvenile and adult sheep skin: implications for developmental and immune regulation.BMC genomics · 2025Article
- An ontology-based knowledge graph for representing interactions involving RNA molecules.Scientific data · 2024Article
- tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB.Journal of experimental & clinical cancer research : CR · 2024Article
- tRNA-derived fragment 3'tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer.Journal of translational medicine · 2024Article
- tRNA-derived small RNAs in human cancers: roles, mechanisms, and clinical application.Molecular cancer · 2024Review
- Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells.Cells · 2024Article
- sRNAfrag: a pipeline and suite of tools to analyze fragmentation in small RNA sequencing data.Briefings in bioinformatics · 2023Article
- 3'-tRF-CysFunctional & integrative genomics · 2023Article
- The Fate and Functionality of Alien tRNA Fragments in Culturing Medium and Cells ofInternational journal of molecular sciences · 2023Article
- Role of tRNA-derived small RNAs(tsRNAs) in the diagnosis and treatment of malignant tumours.Cell communication and signaling : CCS · 2023Review
- NGS Data Repurposing Allows Detection of tRNA Fragments as Gastric Cancer Biomarkers in Patient-Derived Extracellular Vesicles.International journal of molecular sciences · 2023Article
- The role and mechanism of action of tRNA-derived fragments in the diagnosis and treatment of malignant tumors.Cell communication and signaling : CCS · 2023Review
- Characterization of tRNA-Derived Fragments in Lung Squamous Cell Carcinoma with Respect to Tobacco Smoke.International journal of molecular sciences · 2023Article
- Transfer RNA-derived small RNAs (tsRNAs) in gastric cancer.Frontiers in oncology · 2023Review
- Comprehensive landscape of tRNA-derived fragments in lung cancer.Molecular therapy oncolytics · 2022Article
- KRAS-related long noncoding RNAs in human cancers.Cancer gene therapy · 2022Review
- tRNA Function and Dysregulation in Cancer.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tRNA-derived fragments (tRFs) and tRNA halves (tiRNAs) are newly discovered noncoding RNAs in recent years. They are derived from specific cleavage of mature and pre-tRNAs and expressed in various cancers. They enhance cell proliferation and metastasis or inhibit cancer progression. Many studies have investigated their roles in the diagnosis, progression, metastasis, and prognosis of various cancers, but the mechanisms through which they are involved in resistance to cancer treatment are unclear. This review outlines the classification of tRFs and tiRNAs and their mechanisms in cancer drug resistance, thus providing new ideas for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.